Adjuvant Holdings Co Ltd
TSE:4929
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Adjuvant Holdings Co Ltd
Income from Continuing Operations
Adjuvant Holdings Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adjuvant Holdings Co Ltd
TSE:4929
|
Income from Continuing Operations
-ÂĄ99.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shiseido Co Ltd
TSE:4911
|
Income from Continuing Operations
ÂĄ21.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-3%
|
|
Rohto Pharmaceutical Co Ltd
TSE:4527
|
Income from Continuing Operations
ÂĄ31.4B
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
13%
|
|
Pola Orbis Holdings Inc
TSE:4927
|
Income from Continuing Operations
ÂĄ10.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
Kao Corp
TSE:4452
|
Income from Continuing Operations
ÂĄ58.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-3%
|
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
Income from Continuing Operations
ÂĄ17.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
See Also
What is Adjuvant Holdings Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-99.9m
JPY
Based on the financial report for Mar 20, 2024, Adjuvant Holdings Co Ltd's Income from Continuing Operations amounts to -99.9m JPY.